Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses

Clinical Immunology

Volumn 140, Issue 3, 2011, Pages 229-235

  Hogan, Andrew E ^a   Corrigan, Michelle A ^a   O'Reilly, Vincent ^b   Gaoatswe, Gadintshware ^a   O'Connell, Jean ^a   Doherty, Derek G ^b   Lynch, Lydia ^a,c   O'Shea, Donal ^a,d  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c HARVARD MEDICAL SCHOOL   (United States)

^d St Columncille's Hospital   (Ireland)

Author keywords

Anti tumor responses; Cigarette smoke; INKT cells

Indexed keywords

ANTIGEN; CD107 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CIGARETTE SMOKE; GAMMA INTERFERON; INTERLEUKIN 4; UNCLASSIFIED DRUG;

ARTICLE; CELL KILLING; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INVARIANT NATURAL KILLER T CELL; LYMPHOCYTE FUNCTION; NATURAL KILLER T CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION;

ANTIGENS, CD; ANTIGENS, CD56; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; GALACTOSYLCERAMIDES; HELA CELLS; HUMANS; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER T-CELLS; NEOPLASMS; SMOKE; SMOKING; TOBACCO; UP-REGULATION;

EID: 80051795286     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.01.011     Document Type: Article

References (33)

1. Ezzati M., Lopez A.D. Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob. Control 2004, 13:388-395.
2. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999, 91:1194-1210.
3. Stampfli M.R., Anderson G.P. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat. Rev. Immunol. 2009, 9:377-384.
4. Chalmers G.W., MacLeod K.J., Thomson L., Little S.A., McSharry C., Thomson N.C. Smoking and airway inflammation in patients with mild asthma. Chest 2001, 120:1917-1922.
5. Carlens C., Hergens M.P., Grunewald J., Ekbom A., Eklund A., Olgart Hoglund C., Askling J. Smoking, Use of Moist Snuff and Risk of Chronic Inflammatory Diseases. Am. J. Respir. Crit. Care Med. 2010, 181(11):1217-1222.
6. Kim S., Iizuka K., Aguila H.L., Weissman I.L., Yokoyama W.M. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA 2000, 97:2731-2736.
7. Ferson M., Edwards A., Lind A., Milton G.W., Hersey P. Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int. J. Cancer 1979, 23:603-609.
8. Tollerud D.J., Clark J.W., Brown L.M., Neuland C.Y., Mann D.L., Pankiw-Trost L.K., Blattner W.A., Hoover R.N. Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am. Rev. Respir. Dis. 1989, 139:194-198.
9. O'Shea D., Cawood T.J., O'Farrelly C., Lynch L. Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. PLoS ONE 2010, 5:e8660.
10. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 2007, 25:297-336.
11. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., Taniguchi M. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
12. Nieda M., Nicol A., Koezuka Y., Kikuchi A., Takahashi T., Nakamura H., Furukawa H., Yabe T., Ishikawa Y., Tadokoro K., Juji T. Activation of human Valpha24NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Hum. Immunol. 1999, 60:10-19.
13. Exley M., Garcia J., Balk S.P., Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8-T cells. J. Exp. Med. 1997, 186:109-120.
14. Chen H., Paul W.E. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J. Immunol. 1997, 159:2240-2249.
15. Matsuda J.L., Mallevaey T., Scott-Browne J., Gapin L. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr. Opin. Immunol. 2008, 20:358-368.
16. Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., Kaneko Y., Koseki H., Kanno M., Taniguchi M. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997, 278:1623-1626.
17. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Sato H., Kondo E., Harada M., Koseki H., Nakayama T., Tanaka Y., Taniguchi M. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc. Natl. Acad. Sci. USA 1998, 95:5690-5693.
18. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., Balk S.P., Exley M.A. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 2001, 167:4046-4050.
19. Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S., Dhodapkar K.M., Krasovsky J. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 2003, 197:1667-1676.
20. Lynch L., O'Shea D., Winter D.C., Geoghegan J., Doherty D.G., O'Farrelly C. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur. J. Immunol. 2009, 39:1893-1901.
21. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., von Blomberg B.M., Scheper R.J., van der Vliet H.J., van den Eertwegh A.J., Roelvink M., Beijnen J., Zwierzina H., Pinedo H.M. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 2002, 8:3702-3709.
22. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., Abraham R., Juji T., Macfarlane D.J., Nicol A.J. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004, 103:383-389.
23. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M., Iizasa T., Nakayama T., Taniguchi M., Fujisawa T. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 2005, 11:1910-1917.
24. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., Hutchinson A., Geller M., Liu N., Annable R., Shay J., Kirchhoff K., Nishi N., Ando Y., Hayashi K., Hassoun H., Steinman R.M., Dhodapkar M.V. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 2005, 201:1503-1517.
25. Exley M., Porcelli S., Furman M., Garcia J., Balk S. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V alpha 24J alpha Q T cell receptor alpha chains. J. Exp. Med. 1998, 188:867-876.
26. Kawano T., Nakayama T., Kamada N., Kaneko Y., Harada M., Ogura N., Akutsu Y., Motohashi S., Iizasa T., Endo H., Fujisawa T., Shinkai H., Taniguchi M. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 1999, 59:5102-5105.
27. Bernhard D., Huck C.W., Jakschitz T., Pfister G., Henderson B., Bonn G.K., Wick G. Development and evaluation of an in vitro model for the analysis of cigarette smoke effects on cultured cells and tissues. J. Pharmacol. Toxicol. Methods 2004, 50:45-51.
28. Cawood T.J., Moriarty P., O'Farrelly C., O'Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J. Clin. Endocrinol. Metab. 2007, 92:59-64.
29. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 2005, 23:877-900.
30. Molling J.W., Lanigus J.A., Langendijk J.A., Leemans C.R., Bontkes H.J., van der Vliet H.J., von Blomberg M.E., Scheper R.J., van der Eertwegh A.J. Low levels of circulating Invariant Natural Killer T cells predict poor clinical outcome in patients with Head and Neck Squamous Cell Carcinoma. J. Clin. Oncol. 2007, 25:862-868.
31. Dhodapkar K.M. Harnessing human CD1d restricted T cells for tumour immuntiy: progress and challenges. Front. Biosci. 2010, 14:796-807.
32. Nicol A., Nieda M., Koezuka Y., Porcelli S., Suzuki K., Tadokoro K., Durrant S., Juji T. Human invariant Valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 2000, 99:229-234.
33. Lisbonne M., Hachem P., Tonanny M.B., Fourneau J.M., Sidobre S., Kronenberg M., Van Endert P., Dy M., Schneider E., Leite-de-Moraes M.C. In vivo activation of invariant Valpha14 natural killer T cells by alpha-galactosylceramide sequentially induces Fas-dependent and -independent cytotoxicity. Eur. J. Immunol. 2004, 34:1381-1388.